These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32461114)

  • 1. Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs.
    Surve DH; Jindal AB
    J Control Release; 2020 Aug; 324():379-404. PubMed ID: 32461114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection.
    Ullah Nayan M; Sillman B; Hasan M; Deodhar S; Das S; Sultana A; Thai Hoang Le N; Soriano V; Edagwa B; Gendelman HE
    Adv Drug Deliv Rev; 2023 Sep; 200():115009. PubMed ID: 37451501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV.
    Taki E; Soleimani F; Asadi A; Ghahramanpour H; Namvar A; Heidary M
    Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1135-1147. PubMed ID: 35596583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study.
    Parker B; Ward T; Hayward O; Jacob I; Arthurs E; Becker D; Anderson SJ; Chounta V; Van de Velde N
    PLoS One; 2021; 16(2):e0245955. PubMed ID: 33529201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Creation of a long-acting rilpivirine prodrug nanoformulation.
    Hilaire JR; Bade AN; Sillman B; Gautam N; Herskovitz J; Dyavar Shetty BL; Wojtkiewicz MS; Szlachetka A; Lamberty BG; Sravanam S; Fox HS; Alnouti Y; Dash PK; McMillan JM; Edagwa BJ; Gendelman HE
    J Control Release; 2019 Oct; 311-312():201-211. PubMed ID: 31491432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine.
    Hodge D; Back DJ; Gibbons S; Khoo SH; Marzolini C
    Clin Pharmacokinet; 2021 Jul; 60(7):835-853. PubMed ID: 33830459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting injectable antiretrovirals for HIV treatment and prevention.
    Spreen WR; Margolis DA; Pottage JC
    Curr Opin HIV AIDS; 2013 Nov; 8(6):565-71. PubMed ID: 24100877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
    Orkin C; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Overton ET; Girard PM; Oka S; Walmsley S; Bettacchi C; Brinson C; Philibert P; Lombaard J; St Clair M; Crauwels H; Ford SL; Patel P; Chounta V; D'Amico R; Vanveggel S; Dorey D; Cutrell A; Griffith S; Margolis DA; Williams PE; Parys W; Smith KY; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1124-1135. PubMed ID: 32130806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
    Swindells S; Andrade-Villanueva JF; Richmond GJ; Rizzardini G; Baumgarten A; Masiá M; Latiff G; Pokrovsky V; Bredeek F; Smith G; Cahn P; Kim YS; Ford SL; Talarico CL; Patel P; Chounta V; Crauwels H; Parys W; Vanveggel S; Mrus J; Huang J; Harrington CM; Hudson KJ; Margolis DA; Smith KY; Williams PE; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1112-1123. PubMed ID: 32130809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabotegravir and rilpivirine for the treatment of HIV.
    Rial-Crestelo D; Pinto-Martínez A; Pulido F
    Expert Rev Anti Infect Ther; 2020 May; 18(5):393-404. PubMed ID: 32164474
    [No Abstract]   [Full Text] [Related]  

  • 11. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
    Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
    Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission.
    Kovarova M; Council OD; Date AA; Long JM; Nochi T; Belshan M; Shibata A; Vincent H; Baker CE; Thayer WO; Kraus G; Lachaud-Durand S; Williams P; Destache CJ; Garcia JV
    PLoS Pathog; 2015 Aug; 11(8):e1005075. PubMed ID: 26271040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Evaluation of Dissolving Microarray Patches for Co-administered and Repeated Intradermal Delivery of Long-acting Rilpivirine and Cabotegravir Nanosuspensions for Paediatric HIV Antiretroviral Therapy.
    Moffatt K; Tekko IA; Vora L; Volpe-Zanutto F; Hutton ARJ; Mistilis J; Jarrahian C; Akhavein N; Weber AD; McCarthy HO; Donnelly RF
    Pharm Res; 2023 Jul; 40(7):1673-1696. PubMed ID: 36224503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK.
    Rajoli RKR; Flexner C; Chiong J; Owen A; Donnelly RF; Larrañeta E; Siccardi M
    Eur J Pharm Biopharm; 2019 Nov; 144():101-109. PubMed ID: 31525446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation and pharmacology of long-acting rilpivirine.
    Williams PE; Crauwels HM; Basstanie ED
    Curr Opin HIV AIDS; 2015 Jul; 10(4):233-8. PubMed ID: 26049947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study.
    Murray M; Pulido F; Mills A; Ramgopal M; LeBlanc R; Jaeger H; Canon V; Dorey D; Griffith S; Mrus J; Spreen W; Margolis D
    HIV Res Clin Pract; 2019; 20(4-5):111-122. PubMed ID: 31533539
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
    Rizzardini G; Overton ET; Orkin C; Swindells S; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Girard PM; Oka S; Andrade-Villanueva JF; Richmond GJ; Baumgarten A; Masiá M; Latiff G; Griffith S; Harrington CM; Hudson KJ; St Clair M; Talarico CL; Patel P; Cutrell A; Van Eygen V; D'Amico R; Mrus JM; Wu S; Ford SL; Chow K; Roberts J; Wills A; Walters N; Vanveggel S; Van Solingen-Ristea R; Crauwels H; Smith KY; Spreen WR; Margolis DA
    J Acquir Immune Defic Syndr; 2020 Dec; 85(4):498-506. PubMed ID: 33136751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies.
    Hobson JJ; Al-Khouja A; Curley P; Meyers D; Flexner C; Siccardi M; Owen A; Meyers CF; Rannard SP
    Nat Commun; 2019 Mar; 10(1):1413. PubMed ID: 30926773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study.
    Bettonte S; Berton M; Stader F; Battegay M; Marzolini C
    Clin Infect Dis; 2023 Apr; 76(7):1225-1236. PubMed ID: 36377436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rilpivirine long-acting for the prevention and treatment of HIV infection.
    Ferretti F; Boffito M
    Curr Opin HIV AIDS; 2018 Jul; 13(4):300-307. PubMed ID: 29794818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.